DiaMedica Reaches Milestone in Stroke Drug Trial
The company has enrolled 200 patients in a clinical study evaluating the drug DM199 for acute ischemic stroke.
Updated on Oct. 22, 2026 in Stroke
Live Poll
Do you trust pharmaceutical trials that adjust their sample size after they have already begun?
DiaMedica Therapeutics has hit a key enrollment target of 200 patients for its ReMEDy2 clinical trial. This milestone triggers a planned interim analysis of the drug candidate DM199 for treating acute ischemic stroke.
Why it matters
The upcoming interim analysis will determine whether the trial requires a sample size adjustment to maintain statistical power or if it should be stopped for futility. This assessment is crucial for finalizing the clinical path for a potential new stroke therapy.
The ReMEDy2 trial evaluates DM199 versus a placebo over a three-week treatment period, with efficacy measured by a modified Rankin Score of 0 or 1 at 90 days. Trial sample sizes range from 300 to 728 depending on statistical outcomes.
The players
DiaMedica Therapeutics
A biopharmaceutical company based in Minneapolis that specializes in developing treatments for neurological and kidney diseases.
Data Safety Monitoring Board
An independent group of experts that monitors clinical trial data to ensure the safety of participants and the validity of results.
The details
The study employs an adaptive design that excludes patients who have undergone mechanical thrombectomy, focusing on the efficacy of DM199. An independent Data Safety Monitoring Board will oversee the interim analysis to ensure patient safety and data integrity.
Timeline
Q1 2027: Interim analysis expected to be completed.
Health Landscape
The ReMEDy2 clinical trial follows standard industry protocols for testing novel stroke therapeutics in the United States. This interim analysis represents a key governance checkpoint for clinical research programs evaluating emerging treatment modalities.
The trial progress currently impacts research pathways rather than immediate medical options for stroke patients. Participation in this study requires meeting specific eligibility criteria and excludes those who receive mechanical thrombectomy treatment.
The takeaway
This milestone marks a significant step in the evaluation of DM199 as a potential intervention for acute ischemic stroke. Stakeholders should monitor the Q1 2027 analysis for evidence of the drug's efficacy compared to existing treatment outcomes.
What happens next
The independent Data Safety Monitoring Board will complete an interim analysis of the trial data during the first quarter of 2027.
Further reading
For more information on current treatment standards and ongoing research, visit the Stroke section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical trials that adjust their sample size after they have already begun?
